Reverse payment settlements in the context of Article 102 TFEU: Abusive or not? By object or not?
Pharmaceutical reverse payment settlements lie at the intersection of competition law and intellectual property law. In the recent years, these settlement agreements have increasingly attracted the attention of competition law authorities in the European Union. Generally, the focus of these cases, and of the literature concerning reverse payment settlements, has been on the collusive nature of the